Marché du bien-être sexuel des femmes en Amérique du Nord, en Europe et en Asie-Pacifique, par type de test (test Chlamydia Trachomatis et Neisseria Gonorrhoeae (CT/NG), test VHC, test VIH, cancer du col de l'utérus, tuberculose, vaginose bactérienne, test du virus du papillome humain (HPV), herpès génital, complications virales de la transplantation et autres), lieu de test (tests en vente libre, auto-collecte/tests à domicile, tests au point de service et autres), technologie (moléculaire, sérologie, culture/isolement d'organismes et autres), utilisateur final (hôpitaux, cliniques, centres de diagnostic, laboratoires, soins à domicile et autres), canal de distribution (en ligne et hors ligne) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché du bien-être sexuel féminin en Amérique du Nord, en Europe et en Asie-Pacifique
La prise de conscience croissante du bien-être sexuel des femmes a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'amélioration des processus et des techniques contribue également à la demande croissante de bien-être sexuel des femmes.
Le marché devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement, les fabricants se sont engagés dans l'activité de développement pour lancer de nouveaux services et des tests de santé sexuelle efficaces et précis. Le développement croissant des techniques de soins de santé avancées stimule encore davantage la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation de produits de bien-être sexuel pour les femmes devraient freiner la croissance du marché.
L'augmentation des dépenses de santé consacrées au développement et à l'amélioration des produits devrait ouvrir des opportunités au marché. Cependant, le coût élevé des tests pourrait freiner la croissance du marché.
Différentes entreprises prennent des initiatives qui conduisent progressivement à la croissance du marché :
Par exemple,
- En février 2023, BD, une société mondiale de premier plan dans le domaine des technologies médicales, a annoncé l'approbation de la mise sur le marché par la Food and Drug Administration (FDA) des États-Unis du test HPV BD Onclarity à utiliser avec le test Pap ThinPrep. Cette approbation aiderait l'entreprise à améliorer ses produits et à rechercher de nouveaux produits
- En septembre 2020, F. Hoffmann-La Roche Ltd. a annoncé le lancement du test immunologique Elecsys HIV Duo aux États-Unis, après l'approbation de la FDA en avril 2020. Grâce à des mesures séparées de l'antigène p24 du VIH (le virus) et des anticorps anti-VIH (provoqués par une réaction immunitaire), ce test peut détecter une infection aiguë par le VIH . Ce lancement de produit a aidé l'entreprise à élargir son portefeuille de produits
Data Bridge Market Research analyse que le marché nord-américain du bien-être sexuel des femmes devrait atteindre la valeur de 2 834,39 millions USD d'ici 2030, à un TCAC de 9,5 % au cours de la période de prévision.
Data Bridge Market Research analyzes that the Europe Women Sexual Wellness Market is expected to reach the value of USD 1,484.16 million by 2030, at a CAGR of 8.7% during the forecast period.
Data Bridge Market Research analyzes that the Asia-Pacific Women Sexual Wellness Market is expected to reach the value of USD 1,277.82 million by 2030, at a CAGR of 10.3% during the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customisble to 2015-2020) |
|
Quantitative Units |
Revenue in Million, Pricing in USD |
|
Segments Covered |
Test Type (Chlamydia Trachomatis And Neisseria Gonorrhoeae (CT/NG) Test, HCV Test, HIV Test, Cervical Cancer, Tuberculosis, Bacterial Vaginosis, Human Papillomavirus (HPV) Testing, Genital Herpes, Viral Complications With Transplant, and Others), Test Location (Over-The-Counter Testing, Self-Collection/ At Home Testing, Point-Of-Care Testing and Others), Technology (Molecular, Serology, Culture/ Isolation Of Organism, and Others), End User (Hospitals, Clinics, Diagnostic Centers, Laboratories, Home Care Setting, and Others), Distribution Channel (Online and Offline) |
|
Countries Covered |
U.S., Canada, Germany, France, U.K, China, Japan, and Australia |
|
Market Players Covered |
Trinity Biotech, BIOMÉRIEUX, Accuquik Test Kits., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Arbor Vita, Randox Laboratories Ltd., Chembio Diagnostics, Inc., Cepheid., ELITech Group, Abbott, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Sekisui Diagnostics (A Part of SEKISUI Chemical Co. Ltd.), Quidel Corporation, BD., OraSure Technologies, Hologic, Inc., Biomed Diagnostics, and a DCN DX Brand among others. |
North America, Europe and Asia-Pacific Women Sexual Wellness Market Definition
Women's sexual wellness refers to the overall well-being and satisfaction related to a woman's sexual health. Sexual diseases affecting women include various conditions such as Sexually Transmitted Infections (STIs) such as chlamydia, gonorrhea, herpes, Human Papillomavirus (HPV), and syphilis, and other conditions such as vaginal infections, Urinary Tract Infections (UTIs), Pelvic Inflammatory Disease (PID), and hormonal imbalances. The market for women's sexual wellness encompasses a range of diagnostic tools and methods, including laboratory tests, molecular diagnostics, point-of-care testing, imaging techniques, and specialized medical devices.
North America, Europe and Asia-Pacific Women Sexual Wellness Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
A severe global public health concern, sexually transmitted infections (STDs) are becoming more prevalent in diverse locations. The increased prevalence of STDs is significantly influencing the market for women's sexual wellness. It greatly impacts creating and expanding goods and services to enhance sexual health and well-being. Infertility, cervical cancer, and increased susceptibility to HIV are just a few of the long-term effects of STDs and the immediate health hazards they present. Promoting sexual welfare among women worldwide requires addressing the rising rates of STDs.
The followings are a few cases and instances of the rising STD prevalence in North America, Europe, and the Asia-Pacific area to throw light on how it affects the market for women's sexual well-being.
Restraint
- STIGMA AND SOCIAL TABOOS A CHALLENGE
Women's sexual wellness is stigmatized and socially taboo in North America, Europe, and Asia-Pacific, which poses a severe problem. Women encounter obstacles when attempting to access and seek out sexual health services and products due to these societal attitudes and beliefs.
In North America, societal stigma and taboos surrounding sexual matters may make it difficult to address or discuss women's sexual wellness publicly. This stigma may result from societal or religious expectations, which can cause guilt and concern about being judged. Women may be discouraged from seeking out sexual wellness-related information, education, and healthcare services by such attitudes.
In Europe, taboos and societal shame might prevent people from talking openly and accessing support for sexual health. Cultural, religious, and conservative forces may perpetuate the stigma around women's sexual health. Because of this stigma, women may be less likely to seek out sexual health treatments and be less able to make educated choices about their own bodies and sexual needs.
In Asia-Pacific, strongly ingrained cultural and societal standards frequently lead to stigmatization and taboos around women's sexual wellness. Patriarchal structures, conservative views, and limited access to comprehensive sexual education can facilitate the persistence of stigma. Women may hesitate to seek sexual health education, testing, and care out of concern about social stigma, parental or community disapproval, and judgment.
Opportunity
-
INCREASING PRODUCT APPROVALS AND PRODUCT LAUNCHES FOR SEXUAL WELLNESS
Increasing product approvals and product launches present a significant opportunity for the growth of the women's sexual wellness market. The availability of approved products enhances consumer confidence, assuring them of the offerings' safety, efficacy, and quality. It also expands treatment options, providing innovative solutions for conditions such as sexual dysfunction. With improved access and availability of these approved products, the market can reach a more extensive consumer base and address previously unmet needs. Furthermore, the approval and launch of new products stimulate research and innovation, pushing the boundaries of technology and driving market expansion.
Challenge
- LACK OF STANDARDIZATION, GUIDELINES, AND ETHICAL CONSIDERATIONS
The women's sexual wellness market faces a critical issue characterized by the lack of standardization and ethical considerations. This absence of robust guidelines and regulations poses significant challenges for consumers and the industry. One of the primary concerns is the inconsistent quality of products available in the market. In addition, the absence of standardized testing protocols hampers the scientific validation of these products, leading to limited evidence-based knowledge and hindering informed decision-making.
Inconsistent Product Quality: The absence of standardized regulations has led to a wide variation in the quality of women's sexual wellness products in the market. This lack of consistency can jeopardize consumer safety and satisfaction, potentially leading to adverse health effects or ineffective results.
Recent Developments
- In March 2023, Trinity Biotech plc welcomed the Kenyan Ministry of Health's announcement of adopting a new HIV rapid testing algorithm. This new algorithm establishes Trinity Biotech’s TrinScreen HIV as the screening test (A1 = screen test under World Health Organisation (WHO) guidelines)
- In May 2022, Quidel Corporation (“QuidelOrtho”) announced the completion of the transaction combining Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company. The new company is headquartered in San Diego, California. This merger would also help the company expand its business in the clinical diagnostic segment.
North America, Europe and Asia-Pacific Women Sexual Wellness Market Scope
North America, Europe and Asia-Pacific women sexual wellness market is segmented into five notable segments such as test type, test location, technology, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE
- CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
- HCV TEST
- HIV TEST
- CERVICAL CANCER
- TUBERCULOSIS
- BACTERIAL VAGINOSIS
- HUMAN PAPILLOMAVIRUS (HPV) TESTING
- GENITAL HERPES
- VIRAL COMPLICATIONS WITH TRANSPLANT
- OTHERS
On the basis of test type, the market is segmented into Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) test, HCV test, HIV test, cervical cancer, tuberculosis, bacterial vaginosis, Human Papillomavirus (HPV) testing, genital herpes, viral complications with transplant, and others.
NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION
- OVER-THE-COUNTER TESTING
- SELF-COLLECTION/AT HOME TESTING
- POINT-OF-CARE TESTING
- OTHERS
On the basis of test location, the market is segmented into over-the-counter testing, self-collection/ at home testing, point-of-care testing, and others.
NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY
- MOLECULAR
- SEROLOGY
- CULTURE/ISOLATION OF ORGANISM
- OTHERS
On the basis of technology, the market is segmented into molecular, serology, culture/ isolation of organism, and others.
NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER
- HOSPITALS
- CLINICS
- DIAGNOSTIC CENTERS
- LABORATORIES
- HOME CARE SETTING
- OTHERS
On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, laboratories, home care setting, and others.
NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL
- ONLINE
- OFFLINE
On the basis of distribution channel, the market is segmented into online and offline.
North America, Europe and Asia-Pacific Women Sexual Wellness Market Regional Analysis/Insights
The market is categorized into five notable segments: test type, test location, technology, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Germany, France, U.K., China, Japan, and Australia.
The U.S. is expected to dominate the market in North America segment due to the high prevalence of sexual-related diseases such as HIV and HCV in the region. Germany is expected to dominate the market in the Europe segment due to a rise in healthcare expenditure. China is expected to dominate the market in Asia-Pacific segment due to the rising awareness of sexual health.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America, Europe and Asia-Pacific Women Sexual Wellness Market Share Analysis
Le paysage concurrentiel du marché du bien-être sexuel féminin en Amérique du Nord, en Europe et en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché du bien-être sexuel féminin en Amérique du Nord, en Europe et en Asie-Pacifique.
Français Certains des principaux acteurs du marché opérant sur le marché sont Trinity Biotech, BIOMÉRIEUX, Accuquik Test Kits., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Arbor Vita, Randox Laboratories Ltd., Chembio Diagnostics, Inc., Cepheid., ELITech Group, Abbott, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Sekisui Diagnostics (Une partie de SEKISUI Chemical Co. Ltd.), Quidel Corporation, BD., OraSure Technologies, Hologic, Inc., Biomed Diagnostics et une marque DCN DX entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE LIFELINE CURVE (NORTH AMERCA)
2.8 TEST TYPE LIFELINE CURVE (EUROPE)
2.9 TEST TYPE LIFELINE CURVE (ASIA-PACIFIC)
2.1 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.11 DBMR MARKET POSITION GRID
2.12 MARKET TESTING TYPE COVERAGE GRID
2.13 VENDOR SHARE ANALYSIS
2.14 SECONDARY SOURCES
2.15 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 KEY STRATEGIC INITIATIVES
4.4 TREND ANALYSIS
4.4.1 TV (TRICHOMONAS VAGINALIS)
4.4.2 M. GEN (MYCOPLASMA GENITALIUM)
4.4.3 HIV
4.4.4 HBV, HCV (HEPATITIS B & C)
4.4.5 CMV (CYTOMEGALOVIRUS)
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.1.2 GROWING AWARENESS ABOUT STDS
5.1.3 RISE IN THE PREFERENCE FOR HOME CARE TESTING IN WOMEN SEXUAL WELLNESS
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH TESTING
5.2.2 STIGMA AND SOCIAL TABOOS A CHALLENGE
5.3 OPPORTUNITIES
5.3.1 INCREASING PRODUCT APPROVALS AND PRODUCT LAUNCHES FOR SEXUAL WELLNESS
5.3.2 THE INCREASING PRODUCTS APPROVALS AND THEIR LAUNCHES
5.4 CHALLENGES
5.4.1 LACK OF STANDARDIZATION, GUIDELINES, AND ETHICAL CONSIDERATIONS
5.4.2 LACK OF COMPREHENSIVE EDUCATION
6 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 HUMAN PAPILLOMAVIRUS (HPV) TESTING
6.3 GENITAL HERPES
6.4 CERVICAL CANCER
6.4.1 PAP SMEAR TEST
6.4.2 OTHER DIAGNOSTIC TESTS
6.5 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
6.5.1 RAPID TEST KITS
6.5.2 SEROLOGY TESTS
6.5.3 DIRECT FLUORESCENT ANTIBODY TEST
6.5.4 OTHER TEST TYPES
6.6 HIV TEST
6.6.1 ANTIBODY TEST
6.6.2 NUCLEIC ACID TESTS (NATS)
6.6.3 OTHERS
6.7 HCV TEST
6.7.1 HCV ANTIBODY TESTING
6.7.2 HCV VIRAL LOAD TESTING
6.7.3 HCV GENOTYPING TESTING
6.7.4 BACTERIAL VAGINOSIS
6.8 TUBERCULOSIS
6.8.1 CULTURE BASED DIAGNOSIS
6.8.2 SPUTUM SPEAR MICROSCOPY
6.8.3 RAPID MOLECULAR DIAGNOSTICS
6.9 VIRAL COMPLICATIONS WITH TRANSPLANT
6.1 OTHERS
7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION
7.1 OVERVIEW
7.2 POINT-OF-CARE TESTING
7.2.1 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.2.2 GENITAL HERPES
7.2.3 CERVICAL CANCER
7.2.4 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.2.5 HIV TEST
7.2.6 HCV TEST
7.2.7 BACTERIAL VAGINOSIS
7.2.8 TUBERCULOSIS
7.2.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.2.10 OTHERS
7.3 SELF-COLLECTION/AT HOME TESTING
7.3.1 GENITAL HERPES
7.3.2 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.3.3 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.3.4 HIV TEST
7.3.5 HCV TEST
7.3.6 BACTERIAL VAGINOSIS
7.3.7 CERVICAL CANCER
7.3.8 TUBERCULOSIS
7.3.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.3.10 OTHERS
7.4 OVER-THE-COUNTER TESTING
7.4.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.4.2 HCV TEST
7.4.3 GENITAL HERPES
7.4.4 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.4.5 HIV TEST
7.4.6 BACTERIAL VAGINOSIS
7.4.7 CERVICAL CANCER
7.4.8 TUBERCULOSIS
7.4.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.4.10 OTHERS
7.5 OTHERS
8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 SEROLOGY
8.3 MOLECULAR
8.4 CULTURE/ISOLATION OF ORGANISM
8.5 OTHERS
9 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 PUBLIC
9.4 PRIVATE
9.5 CLINICS
9.5.1 WOMEN HEALTHCARE CLINICS
9.5.2 GYNECOLOGY CLINICS
9.5.3 OTHERS
9.6 DIAGNOSTIC CENTERS
9.7 LABORATORIES
9.8 HOME CARE SETTING
9.9 OTHERS
10 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 OFFLINE
10.3 ONLINE
11 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET : BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA.
11.2 EUROPE
11.2.1 GERMANY
11.2.2 U.K.
11.2.3 FRANCE
11.3 ASIA-PACIFIC
11.3.1 HINA
11.3.2 JAPAN
11.3.3 AUSTRALIA
12 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.2 COMPANY SHARE ANALYSIS: EUROPE
12.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 NORTH AMERICA, EUROPE, ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET
14.1 HOLOGIC, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 CEPHEID. (SUBSIDARY OF DANAHER)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 F. HOFFMANN-LA ROCHE LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 ABBOTT
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BIO-RAD LABORATORIES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ACCUQUIK TEST KITS. (ADVACARE PHARMA USA)
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 ARBOR VITA CORPORATION
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 BD.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 BIOMED DIAGNOSTICS, A DCN DX BRAND
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIOMÉRIEUX (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 CHEMBIO DIAGNOSTICS, INC. (2022)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 ELITECH GROUP
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 ORASURE TECHNOLOGIES
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 QUIDEL CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 RANDOX LABORATORIES LTD.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SEKISUI DIAGNOSTICS (A PART OF SEKISUI CHEMICAL CO. LTD.)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 TRINITY BIOTECH (2022)
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 7 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 14 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 29 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 35 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 38 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 47 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 52 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 66 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 68 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 69 U.S. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 75 U.S. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 79 U.S. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 80 U.S. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 U.S. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 U.S. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 85 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 86 CANADA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 92 CANADA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 CANADA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 CANADA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 CANADA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 98 CANADA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 99 CANADA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 101 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 103 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 106 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 107 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 109 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 113 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 117 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 119 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 120 GERMANY CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 GERMANY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 GERMANY HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 124 GERMANY TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 126 GERMANY POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 GERMANY SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 GERMANY OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 130 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 131 GERMANY HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 GERMANY CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 136 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 137 U.K. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.K. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.K. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.K. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 141 U.K. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 143 U.K. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.K. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.K. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 147 U.K. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 U.K. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 149 U.K. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 150 U.K. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 151 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 153 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 154 FRANCE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 155 FRANCE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 156 FRANCE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 157 FRANCE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 158 FRANCE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 160 FRANCE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 FRANCE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 164 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 FRANCE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 166 FRANCE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 168 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 169 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 171 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 172 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 173 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 177 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 179 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 180 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 181 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 182 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 187 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 188 CHINA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 CHINA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 CHINA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 CHINA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 CHINA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 194 CHINA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 CHINA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 CHINA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 197 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 198 CHINA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 CHINA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 200 CHINA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 201 CHINA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 202 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 203 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 204 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 205 JAPAN CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 JAPAN CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 JAPAN HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 JAPAN HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 209 JAPAN TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 211 JAPAN POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 212 JAPAN SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 JAPAN OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 214 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 215 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 216 JAPAN HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 JAPAN CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 218 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 219 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 220 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 221 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 222 AUSTRALIA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 AUSTRALIA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 AUSTRALIA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 225 AUSTRALIA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 AUSTRALIA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 228 AUSTRALIA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 AUSTRALIA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 AUSTRALIA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 232 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 233 AUSTRALIA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 234 AUSTRALIA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 235 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 EUROPE WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 11 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 12 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 13 EUROPE WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 14 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 15 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: VENDOR SHARE ANALYSIS
FIGURE 16 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION
FIGURE 17 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 18 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 19 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 20 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 21 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 22 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 23 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NA, EUROPE AND APAC WOMEN SEXUAL WELLNESS MARKET
FIGURE 24 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 25 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 26 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 27 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 28 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 29 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 30 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 31 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 33 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 34 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 35 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 38 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 39 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 40 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 41 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 43 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 45 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 46 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 47 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 48 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 52 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 53 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 54 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 55 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 56 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 57 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 58 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 59 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 60 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 63 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 64 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 65 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 66 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 67 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 68 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 69 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 70 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 71 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 72 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 73 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 74 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 75 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 76 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 77 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 78 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 79 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 80 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 81 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 82 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 83 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 84 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 85 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 86 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 87 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 88 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 89 EUROPE WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 90 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 91 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 92 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 93 EUROPE WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 94 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 95 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 96 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 97 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 98 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 99 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
FIGURE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
FIGURE 101 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
